OOIR: Observatory of International Research

Papers

(The H4-Index of Movement Disorders is 49. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy	209
Meta‐Analysis of Gut Dysbiosis in Parkinson's Disease	198
Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease	177
Outcome of Parkinson's Disease Patients Affected by COVID‐19	176
Effects of COVID‐19 on Parkinson's Disease Clinical Features: A Community‐Based Case‐Control Study	139
Ten Unsolved Questions About Neuroinflammation in Parkinson's Disease	127
Mental Health, Physical Activity, and Quality of Life in Parkinson's Disease During COVID‐19 Pandemic	120
COVID‐19 in Parkinson’s Disease Patients Living in Lombardy, Italy	119
Impact of the COVID‐19 Pandemic on Parkinson's Disease and Movement Disorders	108
SARS‐CoV‐2: At the Crossroad Between Aging and Neurodegeneration	106
Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression	100
Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression	99
Genome‐Wide Association Studies of Cognitive and Motor Progression in Parkinson's Disease	99
Coronavirus Disease 2019 and Parkinsonism: A Non‐post‐encephalitic Case	90
Parkinson's Disease and COVID‐19: Perceptions and Implications in Patients and Caregivers	88
Blinded RT‐QuIC Analysis of α‐Synuclein Biomarker in Skin Tissue From Parkinson's Disease Patients	85
Guidelines for Speech Recording and Acoustic Analyses in Dysarthrias of Movement Disorders	83
Incidence of Anxiety in Parkinson's Disease During the Coronavirus Disease (COVID‐19) Pandemic	82
Rapid Onset Functional Tic‐Like Behaviors in Young Females During the COVID‐19 Pandemic	81
GBA‐Related Parkinson's Disease: Dissection of Genotype–Phenotype Correlates in a Large Italian Cohort	81
GP2: The Global Parkinson's Genetics Program	76
Global Survey on Telemedicine Utilization for Movement Disorders During the COVID‐19 Pandemic	71
Integrated Care in Parkinson's Disease: A Systematic Review and Meta‐Analysis	70
Genotype–Phenotype Relations for Isolated Dystonia Genes: MDSGene Systematic Review	69
Neuroimaging of Anxiety in Parkinson's Disease: A Systematic Review	67

The Parkinson's Disease Genome‐Wide Association Study Locus Browser	66
Genetic and Environmental Factors in Parkinson's Disease Converge on Immune Function and Inflammation	66
Plasma Short‐Chain Fatty Acids in Patients With Parkinson's Disease	63
Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease	62
Tryptophan Metabolites Are Associated With Symptoms and Nigral Pathology in Parkinson's Disease	61
Synaptic Loss in Primary Tauopathies Revealed by [¹¹C]UCB‐J Positron Emission Tomography	61
Validation of α‐Synuclein in L1CAM‐Immunocaptured Exosomes as a Biomarker for the Stratification of Parkinsonian Syndromes	60
The Role of Cholesterol in α‐Synuclein and Lewy Body Pathology in GBA1 Parkinson's Disease	56
Accelerating Medicines Partnership: Parkinson's Disease. Genetic Resource	56
Nonsteroidal Anti‐inflammatory Use and LRRK2 Parkinson's Disease Penetrance	56
RT‐QuIC Detection of Pathological α‐Synuclein in Skin Punches of Patients with Lewy Body Disease	54
GBA Variants in Parkinson's Disease: Clinical, Metabolomic, and Multimodal Neuroimaging Phenotypes	54
Assessment of Ataxia Rating Scales and Cerebellar Functional Tests: Critique and Recommendations	52
Differences in the Presentation and Progression of Parkinson's Disease by Sex	52
Systematic Assessment of 10 Biomarker Candidates Focusing on α‐Synuclein‐Related Disorders	52
Closed‐Loop Deep Brain Stimulation for Essential Tremor Based on Thalamic Local Field Potentials	52
Loss of Presynaptic Terminal Integrity in the Substantia Nigra in Early Parkinson's Disease	51
International Multicenter Analysis of Brain Structure Across Clinical Stages of Parkinson's Disease	51
Pandemic Tic‐like Behaviors Following Social Media Consumption	51
Bilateral Focused Ultrasound Thalamotomy for Essential Tremor (BEST‐FUS Phase 2 Trial)	50
A Novel SNCA A30G Mutation Causes Familial Parkinsonʼs Disease	50
Coronavirus Disease 2019 Case Fatality and Parkinson's Disease	50
Parkinson's Disease and Post–COVID‐19 Syndrome: The Parkinson's Long‐COVID Spectrum	50
A Phase 1 Randomized Trial of Specific Active α‐Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy	50
Longitudinal Changes in Neuromelanin MRI Signal in Parkinson's Disease: A Progression Marker	49
Brain Microglial Activation Increased in Glucocerebrosidase (GBA) Mutation Carriers without Parkinson's disease	49